Mirivadelgat

Small molecule

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Pulmonary Hypertension Associated with Interstitial Lung Disease

Competitive landscape

This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mirivadelgat: this drugPhase 2Small moleculeALDH2not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results).
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
MosliciguatPhase 3Small moleculeSoluble guanylate cyclasenot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Fc-Relaxin Fusion Protein (TX45)Phase 2Protein / enzyme therapeuticRelaxin receptor (RXFP1) / relaxinnot yet gradedNo reviewed efficacy summary in this indication
LAM-001Phase 2Small moleculemTOR (inhibitor)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Mirivadelgat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
Phase 2Pulmonary Hypertension Associated with Interstitial Lung DiseaseRecruiting
Est. primary completion 2028-02 · NCT06475781 · CT.gov ↗
What to watch

See the full readout calendar ↗